Antibacterial and antifungal drugs intended to prevent or diagnose a serious or life-threatening infection are eligible for designation as a Qualified Infectious Disease Product (QIDP), US FDA says in a new draft guidance document.
However, the guidance confirms that QIDP status extends only to small molecules, and not biologic products or devices.





